Of note, in a recent work by Ricciuti et al., KEAP1 and STK11 mutations were shown to confer worse outcomes (both shorter PFS and OS) only in KRAS-mutated lung adenocarcinoma patients but not among patients with KRAS wild-type [72]. This evidence concerns the gene KRAS and lung adenocarcinoma.